Zyversa Therapeutics, Inc. (ZVSA) SEC Filings — 2025
20 SEC filings for Zyversa Therapeutics, Inc. (ZVSA) in 2025.
Filings
- ZyVersa Therapeutics Reports Officer/Director Changes — 8-K · Dec 3, 2025
- ZyVersa's Q3 Loss Soars on $18.6M R&D Impairment, Cash Dwindles — 10-Q · Nov 19, 2025
- ZyVersa Therapeutics Announces Board and Executive Changes — 8-K · Oct 15, 2025
- ZyVersa Therapeutics Faces Delisting Concerns — 8-K · Sep 18, 2025
- ZyVersa's Cash Dries Up Amid Nasdaq Delisting, Going Concern Doubts — 10-Q · Aug 13, 2025
- ZyVersa Files S-1/A for Continuous Offering, Eyes Capital Infusion — S-1/A · Aug 1, 2025
- ZyVersa Therapeutics Files 8-K — 8-K · Jul 28, 2025
- ZyVersa Amends S-1, Signals Continuous Offering Strategy — S-1/A · Jul 18, 2025
- ZyVersa Therapeutics Faces Delisting Notice — 8-K · Jul 16, 2025
- ZyVersa Therapeutics Files 8-K with Material Agreement — 8-K · Jul 9, 2025
- ZyVersa Files S-1 for Continuous Offering, Signaling Capital Raise — S-1 · Jul 2, 2025
- ZyVersa Therapeutics Files 8-K: Material Agreement & Equity Sales — 8-K · Jun 25, 2025
- ZyVersa Therapeutics Files 8-K on Board Changes and Shareholder Votes — 8-K · Jun 12, 2025
- ZyVersa Therapeutics Faces Delisting Concerns — 8-K · May 30, 2025
- ZyVersa Therapeutics Files Q1 2025 10-Q — 10-Q · May 12, 2025
- ZyVersa Therapeutics Files Definitive Proxy Statement — DEF 14A · Apr 17, 2025
- ZyVersa Therapeutics Changes Certifying Accountant — 8-K · Apr 7, 2025
- ZyVersa Therapeutics Files 2024 10-K — 10-K · Mar 27, 2025
- ZyVersa Therapeutics Reports Material Agreements & Equity Sales — 8-K · Mar 7, 2025
- ZyVersa Therapeutics Files Definitive Proxy Statement — DEF 14A · Jan 17, 2025